| Business Summary | | Shaman
Pharmaceuticals,
Inc.,
through
the
main
operating
division
of
ShamanBotancials.com,
is
focused
on
the
discovery,
development
and
marketing
of
novel,
proprietary
botanical
dietary
supplements
derived
from
tropical
plant
sources.
The
Company's
commercialization
plans
include
the
use
of
community-building
initiatives
on
the
Internet
and
other
distribution
channels,
and
is
based
on
marketing
its
exclusive
access
to
its
proprietary
branded
products.
The
Company
also
has
available
for
out-licensing
a
pipeline
of
botanical
product
candidates,
as
well
as
novel
pharmaceutical
product
candidates
for
major
human
diseases
developed
by
isolating
active
compounds
from
tropical
plants
with
a
history
of
medicinal
use. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Shaman
Pharmaceuticals
is
engaged
in
the
discovery,
development,
and
marketing
of
novel
proprietary
botanical
dietary
supplements
derived
from
tropical
plants
sources
with
a
history
of
medicinal
uses.
For
the
three
months
ended
3/31/01,
revenues
totaled
$232
thousand,
up
from
$53
thousand.
Net
loss
applicable
to
Common
fell
97%
to
$250
thousand.
Results
reflect
license
agreements
revenues,
and
the
absence
of
$2.9
million
in
interest
expense
and
$2.5
million
in
preferred
stock
dividends. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| Lisa Conte, 42 Pres,
CEO, Chief Financial Officer, Director | $232K | Stephen King, Ph.D., 43 COO,
Sr. VP of Ethnobotany and Conservation | 180K | Gerald Reaven, M.D., 72 Sr.
VP, Clinical Research | -- | Thomas White, 42 Sr.
VP of Commercial Strategy and Chief Sales and Marketing Officer | 181K | Thomas Carlson, M.D., 43 VP
of Medical Ethnobotany | 138K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|